Baidu
map

阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗

2019-12-19 不详 MedSci原创

阿斯利康和默克的PARP抑制剂Lynparza已获得FDA的批准,用作BRCA突变、经铂类化学疗法治疗后尚未进展的晚期胰腺癌(一种众所周知的难以治疗的癌症)的维持疗法。

阿斯利康和默克的PARP抑制剂Lynparza已获得FDA的批准,用作BRCA突变、经铂类化学疗法治疗后尚未进展的晚期胰腺癌(一种众所周知的难以治疗的癌症)的维持疗法。

该批准基于Lynparza(olaparib)在晚期BRCA突变胰腺癌患者中3期POLO试验的结果,该试验显示出令人印象深刻的7.4个月无进展生存期(PFS),几乎是安慰剂组3.8个月的两倍。

在这项研究中,PARP抑制剂还使疾病恶化或死亡的风险降低了47%,考虑到胰腺癌的侵袭性,这是一项了不起的成就。

大约5%至6%的胰腺癌是由BRCA基因中的一个或两个突变引起的,BRCA基因突变通常与卵巢癌乳腺癌有关,但在多种肿瘤类型中均可见。

该研究的一个问题在于,Lynparza在总生存率方面无法击败安慰剂。对大约一半的试验人群进行的中期分析显示,Lynparza治疗患者存活中位数为18.9个月,而安慰剂组为18.1个月。

但是,似乎PFS数据以及针对该适应症的治疗选择非常有限,影响了FDA咨询委员会的选择,该委员会最终以7票对5票赞成该药物上市。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839756, encodeId=03261839e5656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jan 17 15:17:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852218, encodeId=0fe71852218ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 03 16:17:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273933, encodeId=0e5412e3933a6, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389574, encodeId=bc5313895e409, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621350, encodeId=21d01621350af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=)]
    2020-01-17 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839756, encodeId=03261839e5656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jan 17 15:17:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852218, encodeId=0fe71852218ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 03 16:17:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273933, encodeId=0e5412e3933a6, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389574, encodeId=bc5313895e409, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621350, encodeId=21d01621350af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=)]
    2020-01-03 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839756, encodeId=03261839e5656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jan 17 15:17:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852218, encodeId=0fe71852218ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 03 16:17:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273933, encodeId=0e5412e3933a6, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389574, encodeId=bc5313895e409, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621350, encodeId=21d01621350af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839756, encodeId=03261839e5656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jan 17 15:17:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852218, encodeId=0fe71852218ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 03 16:17:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273933, encodeId=0e5412e3933a6, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389574, encodeId=bc5313895e409, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621350, encodeId=21d01621350af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839756, encodeId=03261839e5656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jan 17 15:17:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852218, encodeId=0fe71852218ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 03 16:17:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273933, encodeId=0e5412e3933a6, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389574, encodeId=bc5313895e409, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621350, encodeId=21d01621350af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 21 04:17:00 CST 2019, time=2019-12-21, status=1, ipAttribution=)]
    2019-12-21 zhaojie88

相关资讯

阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中,疾病控制率达97.3%

阿斯利康(AstraZeneca)和第一三共(Daiichi Sankyo)提供了新的中期数据,这些数据显示接受靶向HER2的抗体药物偶联物(ADC)trastuzumab(曲妥珠单抗)-deruxtecan(DS-8201)治疗的晚期乳腺癌患者具有"临床意义"的改善。

FDA批准阿斯利康的BTK抑制剂Calquence,用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

美国食品和药物管理局(FDA)批准了阿斯利康的Calquence(acalabrutinib)用于治疗慢性淋巴细胞白血病(CLL)和小淋巴细胞淋巴瘤(SLL)。

2019 AHA:阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

阿斯利康(AstraZeneca)的新数据表明,与安慰剂相比,SGLT2抑制剂Farxiga(dapagliflozin)可以减轻恶化的心力衰竭(HF)(定义为住院、紧急就诊或因心血管事件致死)。

阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险

阿斯利康(AstraZeneca)的TWILIGHT试验的新数据发现,与双重抗血小板治疗(DAPT)相比,Brilinta (ticagrelor)可降低非ST段升高的急性冠状动脉综合症(NSTE-ACS)患者的临床相关性出血风险。

2019 ASH:阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

阿斯利康的BTK抑制剂Calquence在一项III期试验中结果显示了该药物对慢性淋巴细胞性白血病(CLL)患者无进展生存期(PFS)的影响。

FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查

阿斯利康(AstraZeneca)宣布,美国食品药品监督管理局(FDA)已接受其补充生物制剂许可申请(sBLA),并为其靶向程序性的死亡-配体1(PD-L1)单克隆抗体Imfinzi(durvalumab)授予了优先评审资格。

Baidu
map
Baidu
map
Baidu
map